Howland Capital Management LLC Purchases 111 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Howland Capital Management LLC lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 49,965 shares of the company’s stock after acquiring an additional 111 shares during the quarter. Howland Capital Management LLC owned approximately 0.06% of IDEXX Laboratories worth $20,658,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. FSA Wealth Management LLC bought a new position in IDEXX Laboratories in the 3rd quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. boosted its stake in IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after purchasing an additional 57 shares during the period. Retirement Wealth Solutions LLC bought a new position in IDEXX Laboratories in the 4th quarter worth about $31,000. Mowery & Schoenfeld Wealth Management LLC boosted its stake in IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after purchasing an additional 60 shares during the period. Finally, Ashton Thomas Securities LLC bought a new position in IDEXX Laboratories in the 3rd quarter worth about $37,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $459.78 on Friday. The stock’s 50-day moving average is $428.35 and its 200 day moving average is $453.56. The company has a current ratio of 1.31, a quick ratio of 1.03 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The stock has a market cap of $37.65 billion, a price-to-earnings ratio of 43.09, a P/E/G ratio of 3.47 and a beta of 1.37.

Insider Buying and Selling

In related news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now directly owns 905 shares in the company, valued at $380,498.20. This trade represents a 27.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.11% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on IDXX shares. Morgan Stanley cut their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Leerink Partners assumed coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target on the stock. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, Barclays raised their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $524.38.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.